99105-47-2

Upstream product

• 18358-63-9 methyl 4-(N-methyl)aminobenzoate 
• 79-04-9 chloroacetyl chloride 

Downstream Products

• 853069-31-5 methyl 2-{(3R)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-3-(2-chlorobenzyl)-5-methyl-4-oxo-4,5-dihydro-3H-imidazo[4,5-c]quinoline-8-carboxylate 
• 167627-05-6 1-methyl-2-oxoindoline-5-carboxylic acid 
• 1448363-14-1 methyl 4-(2-azido-N-methylacetamido)benzoate 
• 536759-97-4 C₁₅H₂₀N₂O₃ 
• 386213-07-6 1-{2-[(4-methoxycarbonyl-phenyl)-methyl-amino]-ethyl}-1H-indole-2-carboxylic acid ethyl ester 
• 386213-05-4 1-{[(4-methoxycarbonyl-phenyl)-methyl-carbamoyl]-methyl}-1H-indole-2-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

HDAC1,2 INHIBITORS

Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.

Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: Use of a carboxylate prodrug to improve bioavailability

We have previously reported a novel series of 3H-imidazo[4,5-c]quinolin-4(5H)-ones with potent dipeptidyl peptidase IV (DPP-4) inhibitory activity. However, these compounds showed poor oral absorption. We attempted in this study esterification of the carb

Photoinduced and N-bromosuccinimide-mediated cyclization of 2-azido-N-phenylacetamides

An efficient synthesis of quinoxalin-2(1H)-ones or spiro[cyclohexene-1, 2′-imidazol]-4′-ones has been achieved in moderate to high yields by the visible light-induced and N-bromosuccinimide-mediated cyclization reaction of 2-azido-N-phenylacetamides at ambient temperature. Both the regioselectivity and the speed of cyclization are affected by the substituents attached to the phenyl ring. For example, quinoxalin-2-ones are produced as the main products when the substrates bear electron-withdrawing groups at the para-position of the phenyl ring; in contrast, spiro[cyclohexene-1,2′-imidazol]-4′-ones are obtained as the main products when the substrates bear electron-donating groups at the para-position.

GLYCINE B ANTAGONISTS

The invention relates to naphthalene derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

Glycinamides as factor Xa inhibitors

The present application describes glycinamidic compounds and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.